Skip to main content
Top

14-08-2024 | Chronic Kidney Disease | REVIEW Free for a limited time

The Kidney in Obesity: Current Evidence, Perspectives and Controversies

Authors: Dimitris Kounatidis, Natalia G. Vallianou, Theodora Stratigou, Maria Voukali, Irene Karampela, Maria Dalamaga

Published in: Current Obesity Reports

Login to get access

Abstract

Purpose of Review

As obesity and chronic kidney disease (CKD) remain a public health issue, we aim to elaborate on their complex relationship regarding pathogenetic mechanisms and therapeutic potential as well. The purpose of this review is to enhance our understanding of the interplay between obesity and CKD in order to timely diagnose and treat obesity-related CKD.

Recent findings

Obesity and CKD pose significant intertwined challenges to global health, affecting a substantial portion of the population worldwide. Obesity is recognized as an independent risk factor, intricately contributing to CKD pathogenesis through mechanisms such as lipotoxicity, chronic inflammation, and insulin resistance. Recent evidence highlights additional factors including hemodynamic changes and intestinal dysbiosis that exacerbate kidney dysfunction in obese individuals, leading to histologic alterations known as obesity-related glomerulopathy (ORG).

Summary

This narrative review synthesizes current knowledge on the prevalence, pathophysiology, clinical manifestations, and diagnostic strategies of obesity-related kidney disease. Furthermore, it explores mechanistic insights to delineate current therapeutic approaches, future directions for managing this condition and controversies. By elucidating the multifaceted interactions between obesity and kidney health, this review aims to inform clinical practice and stimulate further research to address this global health epidemic effectively.
Literature
9.
10.
go back to reference Brück K, Stel VS, Gambaro G, Hallan S, Völzke H, Ärnlöv J, Kastarinen M, Guessous I, Vinhas J, Stengel B, Brenner H, Chudek J, Romundstad S, Tomson C, Gonzalez AO, Bello AK, Ferrieres J, Palmieri L, Browne G, Capuano V, Van Biesen W, Zoccali C, Gansevoort R, Navis G, Rothenbacher D, Ferraro PM, Nitsch D, Wanner C, Jager KJ, European CKD Burden Consortium. CKD Prevalence Varies across the European General Population. J Am Soc Nephrol. 2016;27(7):2135–47. https://doi.org/10.1681/ASN.2015050542.CrossRefPubMed Brück K, Stel VS, Gambaro G, Hallan S, Völzke H, Ärnlöv J, Kastarinen M, Guessous I, Vinhas J, Stengel B, Brenner H, Chudek J, Romundstad S, Tomson C, Gonzalez AO, Bello AK, Ferrieres J, Palmieri L, Browne G, Capuano V, Van Biesen W, Zoccali C, Gansevoort R, Navis G, Rothenbacher D, Ferraro PM, Nitsch D, Wanner C, Jager KJ, European CKD Burden Consortium. CKD Prevalence Varies across the European General Population. J Am Soc Nephrol. 2016;27(7):2135–47. https://​doi.​org/​10.​1681/​ASN.​2015050542.CrossRefPubMed
24.
go back to reference Cavaliere G, Cimmino F, Trinchese G, Catapano A, Petrella L, D’Angelo M, Lucchin L, Mollica MP. From Obesity-Induced Low-Grade Inflammation to Lipotoxicity and Mitochondrial Dysfunction: Altered Multi-Crosstalk between Adipose Tissue and Metabolically Active Organs. Antioxidants (Basel). 2023;12(6):1172. https://doi.org/10.3390/antiox12061172.CrossRefPubMed Cavaliere G, Cimmino F, Trinchese G, Catapano A, Petrella L, D’Angelo M, Lucchin L, Mollica MP. From Obesity-Induced Low-Grade Inflammation to Lipotoxicity and Mitochondrial Dysfunction: Altered Multi-Crosstalk between Adipose Tissue and Metabolically Active Organs. Antioxidants (Basel). 2023;12(6):1172. https://​doi.​org/​10.​3390/​antiox12061172.CrossRefPubMed
31.
go back to reference Subramanian A, Vernon KA, Zhou Y, Marshall JL, Alimova M, Arevalo C, Zhang F, Slyper M, Waldman J, Montesinos MS, Dionne D, Nguyen LT, Cuoco MS, Dubinsky D, Purnell J, Keller K, Sturner SH, Grinkevich E, Ghoshal A, Kotek A, Trivioli G, Richoz N, Humphrey MB, Darby IG, Miller SJ, Xu Y, Weins A, Chloe-Villani A, Chang SL, Kretzler M, Rosenblatt-Rosen O, Shaw JL, Zimmerman KA, Clatworthy MR, Regev A, Greka A. Protective role for kidney TREM2high macrophages in obesity- and diabetes-induced kidney injury. Cell Rep. 2024;43(6):114253. https://doi.org/10.1016/j.celrep.2024.114253.CrossRefPubMedPubMedCentral Subramanian A, Vernon KA, Zhou Y, Marshall JL, Alimova M, Arevalo C, Zhang F, Slyper M, Waldman J, Montesinos MS, Dionne D, Nguyen LT, Cuoco MS, Dubinsky D, Purnell J, Keller K, Sturner SH, Grinkevich E, Ghoshal A, Kotek A, Trivioli G, Richoz N, Humphrey MB, Darby IG, Miller SJ, Xu Y, Weins A, Chloe-Villani A, Chang SL, Kretzler M, Rosenblatt-Rosen O, Shaw JL, Zimmerman KA, Clatworthy MR, Regev A, Greka A. Protective role for kidney TREM2high macrophages in obesity- and diabetes-induced kidney injury. Cell Rep. 2024;43(6):114253. https://​doi.​org/​10.​1016/​j.​celrep.​2024.​114253.CrossRefPubMedPubMedCentral
33.
go back to reference Lin YT, Chen LK, Jian DY, Hsu TC, Huang WC, Kuan TT, Wu SY, Kwok CF, Ho LT, Juan CC. Visfatin Promotes Monocyte Adhesion by Upregulating ICAM-1 and VCAM-1 Expression in Endothelial Cells via Activation of p38-PI3K-Akt Signaling and Subsequent ROS Production and IKK/NF-κB Activation. Cell Physiol Biochem. 2019;52(6):1398–411. https://doi.org/10.33594/000000098.CrossRefPubMed Lin YT, Chen LK, Jian DY, Hsu TC, Huang WC, Kuan TT, Wu SY, Kwok CF, Ho LT, Juan CC. Visfatin Promotes Monocyte Adhesion by Upregulating ICAM-1 and VCAM-1 Expression in Endothelial Cells via Activation of p38-PI3K-Akt Signaling and Subsequent ROS Production and IKK/NF-κB Activation. Cell Physiol Biochem. 2019;52(6):1398–411. https://​doi.​org/​10.​33594/​000000098.CrossRefPubMed
94.
108.
142.
143.
go back to reference Muscogiuri G, El Ghoch M, Colao A, Hassapidou M, Yumuk V, Busetto L, Obesity Management Task Force (OMTF) of the European Association for the Study of Obesity (EASO). European guidelines for obesity management in adults with a very low-calorie ketogenic diet: A systematic review and meta-analysis. Obes Facts. 2021;14(2):222–45. https://doi.org/10.1159/000515381.CrossRefPubMedPubMedCentral Muscogiuri G, El Ghoch M, Colao A, Hassapidou M, Yumuk V, Busetto L, Obesity Management Task Force (OMTF) of the European Association for the Study of Obesity (EASO). European guidelines for obesity management in adults with a very low-calorie ketogenic diet: A systematic review and meta-analysis. Obes Facts. 2021;14(2):222–45. https://​doi.​org/​10.​1159/​000515381.CrossRefPubMedPubMedCentral
147.
go back to reference Verma S, McGuire DK, Bain SC, Bhatt DL, Leiter LA, Mazer CD, Monk Fries T, Pratley RE, Rasmussen S, Vrazic H, Zinman B, Buse JB. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020;22(12):2487–92. https://doi.org/10.1111/dom.14160.CrossRefPubMedPubMedCentral Verma S, McGuire DK, Bain SC, Bhatt DL, Leiter LA, Mazer CD, Monk Fries T, Pratley RE, Rasmussen S, Vrazic H, Zinman B, Buse JB. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020;22(12):2487–92. https://​doi.​org/​10.​1111/​dom.​14160.CrossRefPubMedPubMedCentral
148.
go back to reference Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T, REWIND Investigators. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomized, placebo-controlled trial. Lancet. 2019;394(10193):131–8. https://doi.org/10.1016/S0140-6736(19)31150-X.CrossRefPubMed Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T, REWIND Investigators. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomized, placebo-controlled trial. Lancet. 2019;394(10193):131–8. https://​doi.​org/​10.​1016/​S0140-6736(19)31150-X.CrossRefPubMed
150.
go back to reference Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP, SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 30 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11–22. https://doi.org/10.1056/NEJMoa1411892.CrossRefPubMed Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP, SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 30 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11–22. https://​doi.​org/​10.​1056/​NEJMoa1411892.CrossRefPubMed
151.
go back to reference Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. https://doi.org/10.1056/NEJMoa2032183.CrossRefPubMed Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. https://​doi.​org/​10.​1056/​NEJMoa2032183.CrossRefPubMed
156.
go back to reference Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW, CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306. https://doi.org/10.1056/NEJMoa1811744.CrossRefPubMed Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW, CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306. https://​doi.​org/​10.​1056/​NEJMoa1811744.CrossRefPubMed
157.
go back to reference Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC, DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46. https://doi.org/10.1056/NEJMoa2024816.CrossRefPubMed Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC, DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46. https://​doi.​org/​10.​1056/​NEJMoa2024816.CrossRefPubMed
161.
go back to reference Heerspink HJL, Agarwal R, Bakris GL, Cherney DZI, Lam CSP, Neuen BL, Sarafidis PA, Tuttle KR, Wanner C, Brinker MD, Dizayee S, Kolkhof P, Schloemer P, Vesterinen P, Perkovic V, FIND-CKD investigators. Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial. Nephrol Dial Transplant. 2024;11:gfae132. https://doi.org/10.1093/ndt/gfae132.CrossRef Heerspink HJL, Agarwal R, Bakris GL, Cherney DZI, Lam CSP, Neuen BL, Sarafidis PA, Tuttle KR, Wanner C, Brinker MD, Dizayee S, Kolkhof P, Schloemer P, Vesterinen P, Perkovic V, FIND-CKD investigators. Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial. Nephrol Dial Transplant. 2024;11:gfae132. https://​doi.​org/​10.​1093/​ndt/​gfae132.CrossRef
168.
174.
go back to reference Papadavid E, Katsimbri P, Kapniari I, Koumaki D, Karamparpa A, Dalamaga M, Tzannis K, Βoumpas D, Rigopoulos D. Prevalence of psoriatic arthritis and its correlates among patients with psoriasis in Greece: results from a large retrospective study. J Eur Acad Dermatol Venereol. 2016;30(10):1749–52. https://doi.org/10.1111/jdv.13700.CrossRefPubMed Papadavid E, Katsimbri P, Kapniari I, Koumaki D, Karamparpa A, Dalamaga M, Tzannis K, Βoumpas D, Rigopoulos D. Prevalence of psoriatic arthritis and its correlates among patients with psoriasis in Greece: results from a large retrospective study. J Eur Acad Dermatol Venereol. 2016;30(10):1749–52. https://​doi.​org/​10.​1111/​jdv.​13700.CrossRefPubMed
175.
176.
go back to reference Dalamaga M, Papadavid E, Basios G, Vaggopoulos V, Rigopoulos D, Kassanos D, Trakakis E. Ovarian SAHA syndrome is associated with a more insulin-resistant profile and represents an independent risk factor for glucose abnormalities in women with polycystic ovary syndrome: a prospective controlled study. J Am Acad Dermatol. 2013;69(6):922–30. https://doi.org/10.1016/j.jaad.2013.09.014.CrossRefPubMed Dalamaga M, Papadavid E, Basios G, Vaggopoulos V, Rigopoulos D, Kassanos D, Trakakis E. Ovarian SAHA syndrome is associated with a more insulin-resistant profile and represents an independent risk factor for glucose abnormalities in women with polycystic ovary syndrome: a prospective controlled study. J Am Acad Dermatol. 2013;69(6):922–30. https://​doi.​org/​10.​1016/​j.​jaad.​2013.​09.​014.CrossRefPubMed
177.
go back to reference Papadavid E, Dalamaga M, Vlami K, Koumaki D, Gyftopoulos S, Christodoulatos GS, Papiris S, Rigopoulos D. Psoriasis is associated with risk of obstructive sleep apnea independently from metabolic parameters and other comorbidities: a large hospital-based case-control study. Sleep Breath. 2017;21(4):949–58. https://doi.org/10.1007/s11325-017-1507-4.CrossRefPubMed Papadavid E, Dalamaga M, Vlami K, Koumaki D, Gyftopoulos S, Christodoulatos GS, Papiris S, Rigopoulos D. Psoriasis is associated with risk of obstructive sleep apnea independently from metabolic parameters and other comorbidities: a large hospital-based case-control study. Sleep Breath. 2017;21(4):949–58. https://​doi.​org/​10.​1007/​s11325-017-1507-4.CrossRefPubMed
183.
go back to reference Dalamaga M, Muscogiuri G, Paganitsa G, Parvouleskou G, Syriou V, Karagkoynis P, Stratigou T, Vallianou N, Christodoulatos GS, Karampela I, Daskalopoulou K. Adherence to the Mediterranean diet is an independent predictor of circulating vitamin D levels in normal weight and non-smoker adults: an observational cross-sectional study. Int J Food Sci Nutr. 2021;72(6):848–60. https://doi.org/10.1080/09637486.2021.1878488.CrossRefPubMed Dalamaga M, Muscogiuri G, Paganitsa G, Parvouleskou G, Syriou V, Karagkoynis P, Stratigou T, Vallianou N, Christodoulatos GS, Karampela I, Daskalopoulou K. Adherence to the Mediterranean diet is an independent predictor of circulating vitamin D levels in normal weight and non-smoker adults: an observational cross-sectional study. Int J Food Sci Nutr. 2021;72(6):848–60. https://​doi.​org/​10.​1080/​09637486.​2021.​1878488.CrossRefPubMed
187.
go back to reference Fryar CD, Gu Q, Ogden CL, Flegal KM. Anthropometric reference data for children and adults: United States, 2011-2014. Vital Health Stat 3 Anal Stud. 2016;39:1–46. Fryar CD, Gu Q, Ogden CL, Flegal KM. Anthropometric reference data for children and adults: United States, 2011-2014. Vital Health Stat 3 Anal Stud. 2016;39:1–46.
193.
Metadata
Title
The Kidney in Obesity: Current Evidence, Perspectives and Controversies
Authors
Dimitris Kounatidis
Natalia G. Vallianou
Theodora Stratigou
Maria Voukali
Irene Karampela
Maria Dalamaga
Publication date
14-08-2024
Publisher
Springer US
Published in
Current Obesity Reports
Electronic ISSN: 2162-4968
DOI
https://doi.org/10.1007/s13679-024-00583-y